Intellia Therapeutics Inc. (NTLA)
Intellia Therapeutics, Inc. (NTLA) Reports Q3 Loss, Tops Revenue Estimates
Intellia Therapeutics, Inc. (NTLA) came out with a quarterly loss of $1.34 per share versus the Zacks Consensus Estimate of a loss of $1.37. This compares to loss of $1.38 per share a year ago.
Intellia Therapeutics Just Notched Another Win. So Why Did Its Stock Fall 18% in 1 Day?
There's nothing bearish at all about what it reported recently.
This Beaten-Down Stock Could Soar by 354%, According to Wall Street
Maybe the Street is a bit too optimistic on this one.
Why Intellia Therapeutics Stock Plummeted by 20% Today
Seemingly encouraging results from the lab were met with some notable skepticism.
Intellia Therapeutics, Inc. (NTLA) Call to Discuss NTLA-2002 Phase 2 Study Results Transcript
Intellia Therapeutics, Inc. (NASDAQ:NTLA ) Call to Discuss NTLA-2002 Phase 2 Study Results Call October 24, 2024 11:00 AM ET Company Participants Lina Li - Senior Director, Investor Relations and Corporate Communications John Leonard - Chief Executive Officer David Lebwohl - Chief Medical Officer. Danny Cohn - Internist, Department of Vascular Medicine, Amsterdam University Medical Center Paula Busse - Professor of Medicine, Division of Clinical Immunology Jim Butler - General Manager, NTLA-2002 Program, Conference Call Participants Luca Issi - RBC Maury Raycroft - Jefferies Mani Foroohar - Leerink Partners Chris Yu - Morgan Stanley Gena Wang - Barclays Dae Gon Ha - Stifel Kostas Biliouris - BMO Capital Markets Rick Bienkowski - Cantor Fitzgerald William Pickering - Bernstein Ray Forset - Guggenheim Timur Ivannikovon - Raymond James Jay Olson - Oppenheimer Operator Good morning, and welcome to the Intellia Therapeutics Investor Event.
2 Biotech Stocks Making Big Moves
The ever-volatile biotech sector is making noise today.
Why Is Gene Therapy-Focused Intellia Therapeutics Stock Trading Lower On Thursday?
On Thursday, Intellia Therapeutics, Inc. NTLA released Phase 2 data from the ongoing Phase 1/2 study of NTLA-2002 in patients with hereditary angioedema (HAE).
Intellia Therapeutics, Inc. (NTLA) Expected to Beat Earnings Estimates: Can the Stock Move Higher?
Intellia Therapeutics (NTLA) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
This Beaten-Down Growth Stock Could Skyrocket 234%, According to Wall Street
Intellia Therapeutics' innovative gene editing technology could revolutionize medicine, but investors need a strong stomach for volatility.
2 Cathie Wood Stocks That Could Soar 32% and 282%, According to Wall Street
These stocks haven't performed well this year.
NTLA Begins Phase III Study on Hereditary Angioedema Candidate
Intellia starts the pivotal phase III HAELO study on NTLA-2002 for the treatment of hereditary angioedema (HAE).
2 Innovative Cathie Wood Stocks to Buy If You Can Stomach the Risk
Cathie Wood invests in businesses that are risky, but with a lot of upside. Intellia Therapeutics has a couple of key readouts coming up.
